Li Jin-Na, Xie Feng, Wang Ying
Department of Oncology, Shengjing Hospital Affiliated to China Medical University, Shenyang 110000, China.
Transl Cancer Res. 2020 Feb;9(2):1001-1011. doi: 10.21037/tcr.2019.12.35.
To observe the effect of bevacizumab in combination with β-elemene on subcutaneous xenografts established from HCT-116 human colon cancer cells, explore the underlying mechanisms involved, and provide more options for the treatment of advanced colorectal cancer.
Mice were randomly divided into four groups: control, β-elemene, bevacizumab and combination treatment. Tumor volume was measured and the tumor inhibition rate and coefficient of drug interaction (CDI) were calculated. The pathological and morphological features of the tumor tissues were observed. Protein expression levels of ki-67, CD31, vascular endothelial growth factor (VEGF) and bcl-2 were measured by immunohistochemistry.
The tumor volumes in the four groups were 0.991±0.131, 0.833±0.145, 0.563±0.131 and 0.324±0.066 cm, respectively. The tumor inhibition rates in the β-elemene, bevacizumab and combination groups were 15.9%, 43.2% and 67.3%, respectively. The degree of tumor reduction in the combination group was the most significant (P<0.05), with a CDI of 0.697. Immunohistochemistry showed that the ki-67 proliferation indexes in the four groups were 30.06%±3.37%, 19.79%±3.75%, 27.51%±2.16% and 16.9%±1.09%, the microvessel densities (MVDs) were 45.86±9.28, 31.14±5.58, 27.57±6.11 and 12.14±3.53, the rates of positive VEGF expression were 39.48%±6.72%, 28.86%±3.54%, 25.04%±2.64% and 19.5%±2.68%, and the rates of positive bcl-2 expression were 33.95%±6.38%, 20.11%±9.49%, 24.28%±6.57% and 11.18%±2.72%, respectively. Compared with the control group, the three experimental groups displayed different degrees of reduction in the above indicators (P<0.05), with the combination group exhibiting the lowest values (P<0.05).
Bevacizumab exerts a synergistic effect with β-elemene in suppressing the growth of tumors derived from HCT-116 cells, and the related mechanisms may include the inhibition of tumor cell proliferation and tumor angiogenesis and the promotion of tumor cell apoptosis.
观察贝伐单抗联合β-榄香烯对人HCT-116结肠癌细胞皮下移植瘤的影响，探讨其潜在作用机制，为晚期结直肠癌的治疗提供更多选择。
将小鼠随机分为四组：对照组、β-榄香烯组、贝伐单抗组和联合治疗组。测量肿瘤体积并计算肿瘤抑制率和药物相互作用系数（CDI）。观察肿瘤组织的病理和形态学特征。采用免疫组织化学法检测ki-67、CD31、血管内皮生长因子（VEGF）和bcl-2的蛋白表达水平。
四组肿瘤体积分别为0.991±0.131、0.833±0.145、0.563±0.131和0.324±0.066 cm。β-榄香烯组、贝伐单抗组和联合组的肿瘤抑制率分别为15.9%、43.2%和67.3%。联合组肿瘤缩小程度最显著（P<0.05），CDI为0.697。免疫组织化学显示，四组的ki-67增殖指数分别为30.06%±3.37%、19.79%±3.75%、27.51%±2.16%和16.9%±1.09%，微血管密度（MVD）分别为45.86±9.28、31.14±5.58、27.57±6.11和12.14±3.53，VEGF阳性表达率分别为39.48%±6.72%、28.86%±3.54%、25.04%±2.64%和19.5%±2.68%，bcl-2阳性表达率分别为33.95%±6.38%、20.11%±9.49%、24.28%±6.57%和11.18%±2.72%。与对照组相比，三个实验组上述指标均有不同程度降低（P<0.05），联合组降低最为明显（P<0.05）。
贝伐单抗与β-榄香烯联合应用对HCT-116细胞来源的肿瘤生长具有协同抑制作用，其相关机制可能包括抑制肿瘤细胞增殖和肿瘤血管生成以及促进肿瘤细胞凋亡。
